Cogent Biosciences Inc (NASDAQ: COGT) has experienced a rise in its stock price by 12.94 compared to its previous closing price of 8.89. However, the company has seen a gain of 6.02% in its stock price over the last five trading days. globenewswire.com reported 2024-12-09 that 56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS
Is It Worth Investing in Cogent Biosciences Inc (NASDAQ: COGT) Right Now?
The 36-month beta value for COGT is at 1.72. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for COGT is 88.93M, and currently, shorts hold a 8.68% of that float. The average trading volume for COGT on December 09, 2024 was 1.16M shares.
COGT’s Market Performance
COGT stock saw a decrease of 6.02% in the past week, with a monthly decline of -0.10% and a quarterly a decrease of -5.99%. The volatility ratio for the week is 3.97%, and the volatility levels for the last 30 days are 5.31% for Cogent Biosciences Inc (COGT). The simple moving average for the past 20 days is 6.43% for COGT’s stock, with a 12.84% simple moving average for the past 200 days.
Analysts’ Opinion of COGT
Many brokerage firms have already submitted their reports for COGT stocks, with Robert W. Baird repeating the rating for COGT by listing it as a “Neutral.” The predicted price for COGT in the upcoming period, according to Robert W. Baird is $8 based on the research report published on February 26, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see COGT reach a price target of $11. The rating they have provided for COGT stocks is “Buy” according to the report published on February 08th, 2024.
Wedbush gave a rating of “Neutral” to COGT, setting the target price at $5 in the report published on December 11th of the previous year.
COGT Trading at -4.80% from the 50-Day Moving Average
After a stumble in the market that brought COGT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.38% of loss for the given period.
Volatility was left at 5.31%, however, over the last 30 days, the volatility rate increased by 3.97%, as shares sank -1.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.71% lower at present.
During the last 5 trading sessions, COGT rose by +6.23%, which changed the moving average for the period of 200-days by +35.22% in comparison to the 20-day moving average, which settled at $9.43. In addition, Cogent Biosciences Inc saw 70.75% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for COGT
Current profitability levels for the company are sitting at:
- -46.61 for the present operating margin
- 0.47 for the gross margin
The net margin for Cogent Biosciences Inc stands at -43.36. The total capital return value is set at -0.79. Equity return is now at value -78.47, with -65.53 for asset returns.
Currently, EBITDA for the company is -205.86 million with net debt to EBITDA at 0.31. When we switch over and look at the enterprise to sales, we see a ratio of 181.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.44.
Conclusion
In conclusion, Cogent Biosciences Inc (COGT) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
